› added 6 years ago
352
TIL Valeant operating practice was gouging patients to beef up their returns while consolidating most of the pharmaceutical industry. Senators found the 30-year-old drug Syprine, which was acquired by Valeant in 2010, has seen a price increase of more than 3,000 per cent.